In this regard, therapies to inhibit the activity of the miR-191/495 cluster would be able to inhibit BC development and progression or alternatively a therapy that overexpress miR-205 would have benefits to reduce the amount of MED1 coactivator, which is a key player in BC development and progression. The gene discussed is MED1; the disease is breast cancer.